Advertisement

Long-Term Endocrine and Exocrine Insufficiency After Pancreatectomy

  • Jiro Kusakabe
  • Blaire Anderson
  • Jingxia Liu
  • Gregory A. Williams
  • William C. Chapman
  • Majella M. B. Doyle
  • Adeel S. Khan
  • Dominic E. Sanford
  • Chet W. Hammill
  • Steven M. Strasberg
  • William G. Hawkins
  • Ryan C. FieldsEmail author
Original Article
  • 75 Downloads

Abstract

Purpose

To identify peri-operative risk factors and time to onset of pancreatic endocrine/exocrine insufficiency.

Methods

We retrospectively analyzed a single institutional series of patients who underwent pancreaticoduodenectomy (PD) or distal pancreatectomy (DP) between 2000 and 2015. Endocrine/exocrine insufficiencies were defined as need for new pharmacologic intervention. Cox proportional modeling was used to identify peri-operative variables to determine their impact on post-operative pancreatic insufficiency.

Results

A total of 1717 patient records were analyzed (75.47% PD, 24.53% DP) at median follow-up 17.88 months. Average age was 62.62 years, 51.78% were male, and surgery was for malignancy in 74.35% of patients. Post-operative endocrine insufficiency was present in 20.15% (n = 346). Male gender (p = 0.015), increased body mass index (BMI) (p < 0.001), tobacco use (p = 0.011), family history of diabetes (DM) (p < 0.001), personal history of DM (p ≤ 0.001), and DP (p ≤ 0.001) were correlated with increased risk. Mean time to onset was 20.80 ± 33.60 (IQR: 0.49–28.37) months. Post-operative exocrine insufficiency was present in 36.23% (n = 622). Race (p = 0.014), lower BMI (p < 0.001), family history of DM (p = 0.007), steatorrhea (p < 0.001), elevated pre-operative bilirubin (p = 0.019), and PD (p ≤ 0.001) were correlated with increased risk. Mean time to onset was 14.20 ± 26.90 (IQR: 0.89–12.69) months.

Conclusions

In this large series of pancreatectomy patients, 20.15% and 36.23% of patients developed post-operative endocrine and exocrine insufficiency at a mean time to onset of 20.80 and 14.20 months, respectively. Patients should be educated regarding post-resection insufficiencies and providers should have heightened awareness long-term.

Keywords

Pancreaticoduodenectomy Distal pancreatectomy Pancreatic endocrine insufficiency Pancreatic exocrine insufficiency Pancreatic enzyme replacement 

Notes

Grant Support and Other Assistance

G.A.W. and J.L. supported by the SPORE grant 5P50CA196510-02. REDCap Supported by Clinical and Translational Science Award (CTSA) Grant [UL1 TR000448] and Siteman Comprehensive Cancer Center and NCI Cancer Center Support Grant P30 CA091842.

Authors’ Contribution

J.K., B.A. participated in study conception and design, analysis, and drafting of the article.

J.L., G.A.W., W.C.C., M.M.B.D., A.S.K., D.E.S., C.W.H., S.M.S., W.G.H. participated in acquisition of data, analysis, and interpretation of data.

R.C.F. participated in study conception and design, acquisition of data, analysis, and interpretation of data, and critical revision of the manuscript.

References

  1. 1.
    Cameron JL. He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220:530–536. CrossRefGoogle Scholar
  2. 2.
    Fernández-del Castillo C, Morales-Oyarvide V, McGrath D, Wargo JA, Ferrone CR, Thayer SP, Lillemoe KD, Warshaw AL. Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery. 2012;152:S56–S63.CrossRefGoogle Scholar
  3. 3.
    Venkat R, Edil BH, Schulick RD, Lidor AO, Makary MA, Wolfgang CL. Laparoscopic distal pancreatectomy is associated with significantly less overall morbidity compared to the open technique: A systematic review and meta-analysis. Ann Surg. 2012;255:1048–1059.CrossRefGoogle Scholar
  4. 4.
    Huang JJ, Yeo CJ, Sohn TA, Lillemoe KD, Sauter PK, Coleman J, Hruban RH, Cameron JH. Quality of life and outcomes after pancreaticoduodenectomy. Ann Surg. 2000;231:890–898.CrossRefGoogle Scholar
  5. 5.
    Cherif, R, Gaujoux S, Couvelard A, Dokmak S, Vuillerme MP, Ruszniewski P, Belghiti J, Sauvanet A. Parenchyma-sparing resections for pancreatic neuroendocrine tumors. J Gastrointest Surg. 2012;16:2045–2055.CrossRefGoogle Scholar
  6. 6.
    Falconi M, Mantovani W, Crippa S, Masetta G, Salvia R, Pederzoli P. Pancreatic insufficiency after different resections for benign tumors. Br J Surg. 2008;95:85–91.CrossRefGoogle Scholar
  7. 7.
    Crippa S, Bassi C, Warshaw AL, Falconi M, Stefano P, Thayer SP, Pederzoli P, Castillo CFD. Middle pancreatectomy. Ann Surg. 2007;246:69–76.CrossRefGoogle Scholar
  8. 8.
    Falconi M, Zerbi A, Crippa S, Balzano G, Boninsegna L, Capitanio V, Bassi C, Di Carlo V, Pederzoli P. Parenchyma-preserving resections for small nonfunctioning pancreatic endocrine tumors. Ann Surg Oncol. 2010;17:1621–1627.CrossRefGoogle Scholar
  9. 9.
    Whitcomb DC, Yadav D, Adam S, Hawes RH, Brand RE, Anderson MA, Money ME, Banks PA, Bishop MD, Baillie J, Sherman S, Disario J, Burton FR, Gardner TB, Amann ST, Gelrud A, Lo SK, DeMeo MT, Steinberg WM, Kockman ML, Etemad B, Forsmark CE, Elinoff B, Greer JB, O’Connell M, Lamb J, Barmada MM. Multicenter approach to recurrent acute and chronic pancreatitis in the United States: The North American Pancreatitis Study 2 (NAPS2). Pancreatology. 2008; 8:520–531.CrossRefGoogle Scholar
  10. 10.
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457–481.CrossRefGoogle Scholar
  11. 11.
    Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50:163–170.Google Scholar
  12. 12.
    Cox, DR. Regression models and life-tables. Journal of the Royal Statistical Society, Series B. 1972;34:187–220.Google Scholar
  13. 13.
    Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. New York: Springer; 1997:229–263.CrossRefGoogle Scholar
  14. 14.
    Lim PW, Dinh KH, Sullican M, Wassef WY, Zivny J, Whalen GF, LaFemina J. Thirty-day outcomes underestimate endocrine and exocrine insufficiency after pancreatic resection. HPB. 2016;18:360–366.CrossRefGoogle Scholar
  15. 15.
    Phillips ME. Pancreatic exocrine insufficiency following pancreatic resection. Pancreatology. 2015;15:449–455.CrossRefGoogle Scholar
  16. 16.
    Seiler CM, Izbicki J, Vargas-Szabo L, Czak L, Fiok J, Sperti C, Lerch MM, Pezzilli R, Vasileva G, Pap A, Varga M, Friess H. Randomised clinical trial: A 1-week, double-blinded, placebo-controlled study of pancreatin 25 000 Ph. Eur minimicrospheres (Creon 25000 MMS) for pancreatic exocrine insufficiency after pancreatic surgery, with a 1-year open-label extension. Aliment Pharmacol Ther. 2013;37:691–702.CrossRefGoogle Scholar
  17. 17.
    Halloran CM, Cox TF, Chauhan S, Raraty MG, Sutton R, Neoptolemos JP, Ghaneh P. Partial pancreatic resection for pancreatic malignancy is associated with sustained pancreatic exocrine failure and reduced quality of life: A prospective study. Pancreatology. 2012;11:535–545.CrossRefGoogle Scholar
  18. 18.
    American Diabetes Association. 2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes – 2018. Diabetes Care. 2018;41:S13.CrossRefGoogle Scholar
  19. 19.
    Hirata K, Nakata B, Amano R, Yamazoe S, Kimura K, Hirakawa K. Predictive factors for change of diabetes mellitus status after pancreatectomy in preoperative diabetic and nondiabetic patients. J Gastrointest Surg. 2014;18:1597–1603.CrossRefGoogle Scholar
  20. 20.
    White MA, Agle SC, Fuhr HM, Mehaffey JH, Waibel BH, Zervos EE. Impact of pancreatic cancer and subsequent resection on glycemic control in diabeteic and nondiabetic patients. Am Surg. 2011;77:1032–1037.Google Scholar
  21. 21.
    Dinorcia J, Ahmed L, Lee MK, Reavey PL, Yakaitis Ea, Lee JA, Schrope BA, Chabot JA, Allendorf JD. Better preservation of endocrine function after central versus distal pancreatectomy for mid-gland lesions. Surgery. 2010;148:1247–1254.CrossRefGoogle Scholar
  22. 22.
    Kwon JH, Kim SC, Shim IK, Song KB, Lee JH, Hwang DW, Park KM, Lee YJ. Factors affecting the development of diabetes mellitus after pancreatic resection. Pancreas. 2015;44:1296–1303.CrossRefGoogle Scholar
  23. 23.
    Gersell DJ, Gingerich RL, Greider MH. Regional distribution and concentration of pancreatic polypeptide in the human and canine pancreas. Diabetes. 1979;28:11–15.CrossRefGoogle Scholar
  24. 24.
    Henquin JC, Ibrahim MM, Rahier J. Insulin, glucagon and somatostatin stores in the pancreas of subjects with type-2 diabetes and their lean and obese non-diabetic controls. Sci Rep. 2017;7:1–9.CrossRefGoogle Scholar
  25. 25.
    Kachare SD, Fitzgerald TL, Schuth O, Vohra NA, Zervos EE. The impact of pancreatic resection on exocrine homeostasis. Am Surg. 2014;80:704–709.Google Scholar
  26. 26.
    Strasberg SM, Gao F, Sanford D, Linehan DC, Hawkins WG, Fields RC, Carpenter DH, Brunt EM, Phillips C. Jaundice: an important, porrly recognized risk factor for diminished survival with adenocarcinoma of the head of the pancreas. HPB. 2014;16:150–156.CrossRefGoogle Scholar
  27. 27.
    Beger HG, Nakao A, Mayer B, Porch B. Duodenum-preserving total and partial pancreatic head resection for benign tumors – systematic review and meta-analysis. Pancreatology. 2015;15:167–178.CrossRefGoogle Scholar
  28. 28.
    Vujasinovic M, Valente R, Del Chiaro M, Permert J, Lohr JM. Pancreatic exocrine insufficiency in pancreatic cancer. Nutrients. 2017;9:183.CrossRefGoogle Scholar
  29. 29.
    Lemaire E, O’Toole D, Sauvanet A, Hammel P, Belghiti J, Ruszniewski P. Functional and morphological changes in the pancreatic remnant following pancreaticoduodenectomy with pancreaticogastric anastomosis. Br J Surg. 2000;87:434–438.CrossRefGoogle Scholar
  30. 30.
    Gemici C, Sargin M, Uygur-Bayramicli O, Mayadagli A, Yaprak G, Dabak R, Kocak M. Risk of endocrine insufficiency in patients receiving adjuvant chemoradiation for resected gastric cancer. Radiother Oncol. 2013; 107, 195–199.CrossRefGoogle Scholar
  31. 31.
    Wu JM, Ho TW, Kuo TC, Yang CY, Lai HS, Chiang PY, Hsieh SH, Lai F, Tien YW. Glycemic change after pancreaticoduodenectomy: A population-based study. Medicine (Baltimore). 2015l94:e1109.Google Scholar
  32. 32.
    Ferrara MJ, Lohse C, Kudva YC, Farnell MB, Que FG, Reid-Lombardo KM, Donohue JH, Nagorney DM, Chari ST, Vege SS, Kendrick ML. Immediate post-resection diabetes mellitus after pancreaticoduodenectomy: Incidence and risk factors. HPB. 2013;15:170–174.CrossRefGoogle Scholar
  33. 33.
    Orfanidis NT, Loren DE, Santos C, Kennedy EP, Siddiqui AA, Lavu H, Yeo CJ, Kowalski TE. Extended follow-up and outcomes of patients undergoing pancreaticoduodenectomy for no-malignant disease. J Gastrointest Surg. 2012;16:80–88.CrossRefGoogle Scholar
  34. 34.
    Elliott IA, Epelboym I, Winner M, Allendorf JD, Haigh PI. Population-level incidence and predictors of surgically induced diabetes and exocrine insufficiency after partial pancreatic resection. Perm J. 2017; 21:16–095.Google Scholar
  35. 35.
    Beger HG, Poch B, Mayer B, Siech M. New onset of diabetes and pancreatic exocrine insufficiency after pancreaticoduodenectomy fo benign and malignant tumors: A systematic review and meta-analysis of long-term results. Ann Surg. 2018;267:259–270.CrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2019

Authors and Affiliations

  • Jiro Kusakabe
    • 1
  • Blaire Anderson
    • 1
  • Jingxia Liu
    • 1
  • Gregory A. Williams
    • 1
  • William C. Chapman
    • 1
  • Majella M. B. Doyle
    • 1
  • Adeel S. Khan
    • 1
  • Dominic E. Sanford
    • 1
  • Chet W. Hammill
    • 1
  • Steven M. Strasberg
    • 1
  • William G. Hawkins
    • 1
  • Ryan C. Fields
    • 1
    Email author
  1. 1.Department of Surgery, Barnes-Jewish Hospital and the Alvin J. Siteman Cancer CenterWashington University School of MedicineSt. LouisUSA

Personalised recommendations